Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Seegene announced Health Canada authorized the import and sale in of Allplex™ 2019-nCoV Assay, a Real-time RT-PCR test for SARS-CoV-2.
read more
Sekisui Diagnostics Enzyme business announces the completion of a new BioProcess Innovation Centre at the site in Maidstone, Kent by the end of 2019, following a $1.9 million investment.
read more
SEKISUI XenoTech will celebrate its 25th anniversary this November, coming into the year with record-breaking achievements.
read more
Sekisui XenoTech now offers human liver tissue microarrays and a microsomal pool for studying and developing new treatments for fatty liver disease.
read more
Thursday, October 19, 2017
Sekisui XenoTech announced the appointment of Dr. Darren Warren, PhD, as the company’s new Chief Operating Officer.
read more
Wednesday, August 16, 2017
Sekisui XenoTech announced the addition of the H0606.S9(AX) Pooled Human Liver S9 and H0606.C(AX) Pooled Human Liver Cytosol test systems to the company’s catalog of in vitro drug development products.
read more
Wednesday, August 03, 2016
Sekisui XenoTech has added additional hepatotoxicity screening assays and methodologies to the company’s existing cytotoxicity contract research services. Cytotoxicity studies assess the risk that test articles may cause toxicity in cells, with ...
read more
Sekisui XenoTech has been awarded US patent # 10,001,471 “In vitro test system to evaluate xenobiotics as immune-modulators of drug transport and metabolism in human hepatocytes.”
read more
Sekisui XenoTech's Analytical Services lab provides researchers with custom method development and method validation, dose solution analysis, in vitro and in vivo metabolite profiling studies.
read more
Selexis SA and KBI Biopharm, announced that they have signed service agreements with Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies.
read more
Wednesday, January 09, 2019
Selexis has signed additional CLAs with Agenus, an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, and adoptive cell therapies.
read more
Wednesday, September 26, 2018
Selexis SA and Hoba Therapeutics announced they have entered into an agreement to advance the development of Hoba’s clinical candidate HB-086 for peripheral neuropathic pain.
read more
Tuesday, September 26, 2017
Selexis and OSE announced the signing of two CLAs that provide OSE with access to high-performance RCBs developed using the Selexis SUREtechnology Platform.
read more
Friday, February 16, 2024
Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, announced the Aseptic Process Simulation (APS) qualification of its ...
read more
Selkirk Pharma, Inc. announced the appointment of Colleen Dixon as the company’s new Chief Executive Officer. Dixon, who formerly served as Vice President of Program Management at Selkirk Pharma, succeeds Patrick Haffey, the founder of Selkirk Pharma...
read more